Leo sues Perrigo for patent infringement over skin gel
Leo Pharma has filed suit against Perrigo in the US District Court for the District of Delaware alleging patent infringement.
This filing of the suit, on June 10, follows Perrigo’s filing of Abbreviated New Drug Applications with the US Food and Drug Administration for ingenol mebuttae gel (0.015% and 0.05%), which are generic versions of Leo’s Picato gel.
Leo’s filing of the suit started the litigation process under the Hatch-Waxman Act.
Picato is a prescription medication for treatment of actinic keratosis, which is a skin condition from overexposure to the sun.
In a statement, Perrigo’s CEO, John Hendrickson, said: “This filing illustrates Perrigo’s commitment to providing quality affordable healthcare products”.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk